Statins and survival outcomes in patients with metastatic renal cell carcinoma
作者: Rana R. McKayXun LinLaurence AlbigesAndre P. FayMarina D. KaymakcalanSuzanne S. MickeyPaiman P. GhoroghchianRupal S. BhattSamuel D. KaffenbergerRonit SimantovToni K. ChoueiriDaniel Y.C. Heng
作者单位: 1Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
2Pfizer Oncology, Pfizer Inc., 235 East 42nd Street, New York, NY, 10017 USA
3Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA
4Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10065, USA
5Department of Medical Oncology, Tom Baker Cancer Center, 1331 29 Street Northwest, Calgary, AB T2N 4N2, Canada
刊名: European Journal of Cancer, 2016, Vol.52 , pp.155-162
来源数据库: Elsevier Journal
DOI: 10.1016/j.ejca.2015.10.008
关键词: HMG-CoA reductase inhibitorsPrognosisRenal cell carcinomaStatinsTargeted therapy
英文摘要: Abstract(#br)Background(#br)A growing body of evidence has demonstrated the anti-neoplastic activity of statins. The objective of this study was to investigate the effect of statin use on survival in patients with metastatic renal cell carcinoma (mRCC) treated in the modern therapy era.(#br)Patients and methods(#br)We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression and the Kaplan–Meier method.(#br)Results(#br)We identified 4736 patients treated with sunitinib ( n =1059), sorafenib ( n =772), axitinib ( n =896), temsirolimus ( n =457),...
全文获取路径: Elsevier  (合作)
影响因子:5.061 (2012)

  • survival 生存
  • carcinoma 癌症
  • metastatic 新陈代谢的
  • renal 肾的